Saiertech was founded in September 2005 with a registered capital of Rmb 11 million and launched its building in August 2006. In July 2007, Saiertech kicked off its trial production of 3 batches of national standard Anti Rh(D) Blood Grouping Reagent. The company's capital increased to Rmb 30 million in 2008.
Covering an area of 9,778m2, Saiertech has finished its first phase of construction including its 6,200m2 GMP workshop, 400m2 QA workshop, 400m2 R&D lab, and 1,000m2 Administration area.
With diagnosis-oriented monoclonal antibody (McAb) as its primary product, Saiertech is devoted to developing, producing, and selling diagnosis-oriented McAB Reagents, ELISA kits, TRFIA kits, as well as other bio-medical products.
Saiertech has been in long term "production, teaching and research" cooperation ...... |
Suzhou University is a research base to Suzhou University, as technical support and source of scientific and technological achievements, forming a "capital - technology - Market integration" model of medical research. Most of the products from the company subsidiary, Jiangsu Province, Suzhou University Blood Institute, Clinical Immunology Research Institute of biological high-tech achievements of independent innovation, the transformation over the course of providing full technical guidance, Suzhou University Animal Experiment Center, Institute of Nuclear Medicine provide logistical support. Suzhou University for the provision of results into a platform with the internship location, to participate in Suzhou University undergraduate, postgraduate training job.
In addition, the company is also well-known domestic and foreign research institutes, institutions of higher learning and high-tech industry maintained a fruitful exchange and cooperation. Such as France's Pasteur Institute, Scientific Center of Genetics, General Hospital, Montpellier, Nantes University, Japan, Kanazawa University Cancer Institute, University of Tokyo, health clinics, Germany Humboldt University, University of Pittsburgh School of Medicine and so on. |
|
The company has a high knowledge level, young and dynamic start-up team, a total of 45 employees, of which one person has Academician, Professor Doctor 3 people, 3 people, Senior Engineer, Chief Physician and technician and deputy director of 4 people, 2 person division advanced experiments, an associate researcher at the 2 people, 2 person licensed pharmacist. More than well-known expert for the company leader. Include:
RUAN Chang-geng, Chinese Academy of Engineering, Su major shareholder and chief scientist of Purcell and graduated from Beijing University in Biochemistry Department of Biology, University of Paris, France, seventh Institute of Hematology, St. Louis hospital studies, was French country doctor (hematology) degree. Blood current director of the Institute of Jiangsu Province, Jiangsu Province, nuclear medicine, director of Key Laboratory of Biotechnology, Jiangsu Association for Science and Technology Vice-President, Chinese Society of Hematology, vice chairman, the Chinese Society of Experimental blood, vice ...... |
Company in April 2007 to complete the basic infrastructure, job debugging, and built GMP production workshop 6200 ㎡, 400 ㎡ workshop quality control, R & D Center 2500 ㎡, 1000 ㎡ operational management, and through the city of Xuzhou Detect Drug Administration GMP environment.
May 2007 through省局acceptance, access to pharmaceutical manufacturing enterprise license.
In February 2008 to obtain a permit medical equipment manufacturing enterprises.
May 2008 to obtain medical equipment business license, business license in vitro diagnostic reagents.
June 2008 through the State Food and Drug Administration Quality System in vitro diagnostic test reagent.
In October 2008 the organization of national experts through the ministries and agencies of the provincial assessment results into major ...... |
|
